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ARTICLE
PALB2 chromatin recruitment restores homologous
recombination in BRCA1-deficient cells depleted of
53BP1
Rimma Belotserkovskaya 1,2*, Elisenda Raga Gil1,2,4, Nicola Lawrence 1, Richard Butler1, Gillian Clifford3,
Marcus D. Wilson 3* & Stephen P. Jackson 1,2*
Loss of functional BRCA1 protein leads to defects in DNA double-strand break (DSB) repair
by homologous recombination (HR) and renders cells hypersensitive to poly (ADP-ribose)
polymerase (PARP) inhibitors used to treat BRCA1/2-deficient cancers. However, upon
chronic treatment of BRCA1-mutant cells with PARP inhibitors, resistant clones can arise via
several mechanisms, including loss of 53BP1 or its downstream co-factors. Defects in the
53BP1 axis partially restore the ability of a BRCA1-deficient cell to form RAD51 filaments at
resected DSBs in a PALB2- and BRCA2-dependent manner, and thereby repair DSBs by HR.
Here we show that depleting 53BP1 in BRCA1-null cells restores PALB2 accrual at resected
DSBs. Moreover, we demonstrate that PALB2 DSB recruitment in BRCA1/53BP1-deficient
cells is mediated by an interaction between PALB2’s chromatin associated motif (ChAM) and
the nucleosome acidic patch region, which in 53BP1-expressing cells is bound by 53BP1’s
ubiquitin-directed recruitment (UDR) domain.
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Homologous recombination (HR) is largely an error-freepathway in which the sister chromatid is used as a tem-plate for repairing genetic information in the damaged
DNA molecule. For HR to ensue, a tract of single-stranded DNA
(ssDNA) with a 3′ overhang is first generated by the concerted
actions of endo- and exonucleases such as MRE11, CtIP, EXO1
and DNA2 in a process called DNA end-resection1. Resected
DNA is rapidly coated with replication protein A (RPA) multi-
mers that protect ssDNA from both nucleolytic degradation and
self-hybridisation to form complex secondary structures. Subse-
quently, RPA is replaced by the RAD51 recombinase protein to
form a nucleoprotein filament competent for invasion of the
homologous DNA template. This step is promoted by BRCA2,
which binds several molecules of RAD51 delivering them to the
RPA-coated ssDNA and, together with other factors, facilitates
replacement of RPA with RAD512,3.
BRCA1 promotes HR in at least two functionally and tempo-
rally distinct stages: first, by modulating the kinetics of DNA end-
resection4,5 and later by promoting RAD51 filament formation
via recruiting the PALB2-BRCA2-RAD51 complex to RPA-
coated ssDNA6,7. Interfering with either of these steps results in
HR impairment, a key hallmark of BRCA1 deficiency. As loss of
53BP1 or its downstream effectors partially rescues the HR defect
of cells lacking functional BRCA18,9, an important unresolved
question is how this is achieved: does it act by rebalancing DNA
end-resection, by restoring proficient RAD51 loading, or both?
Herein, we employed a combination of cell biology and bio-
chemical approaches to understand the recruitment of PALB2 to
sites of DNA DSBs. We find that in the absence of BRCA1, loss of
53BP1 creates a permissive environment for PALB2 recruitment.
We show that in BRCA1/53BP1-deficient cells, PALB2 accumula-
tion into DNA-damage-induced foci requires the intact Chromatin
Association Motif (ChAM), which mediates a direct interaction with
the acidic patch of the nucleosome. Our findings elucidate the role
of PALB2 in promoting HR and help to explain how DNA repair
can be restored in clinically relevant BRCA1/53BP1-deficient cells.
Results
53BP1 loss restores HR in BRCA1- but not PALB2-depleted
cells. To address how HR can be restored in the absence of
BRCA1, we characterised the impacts of 53BP1 on various stages
of HR in cells depleted for BRCA1, PALB2 or BRCA2. In gene
conversion assays using the traffic light reporter (TLR) system
integrated into human U2OS cells10,11, short-interfering RNA
(siRNA)-mediated depletion of BRCA1, PALB2 or
BRCA2 severely inhibited HR (Fig. 1a, b). Furthermore, con-
sistent with previous studies8,9, 53BP1 depletion partially rescued
the HR defect of BRCA1-depleted cells. Notably however, 53BP1
depletion did not rescue the HR defect of PALB2- or BRCA2-
depleted cells (Fig. 1a; the latter is in agreement with the obser-
vations that 53BP1 loss did not rescue viability of Brca2−/−
mouse cells9 or the HR defect of Palb2-deficient mouse cells12).
Nevertheless, while 53BP1 depletion consistently enhanced HR
up to threefold in the BRCA1-depleted background, HR never
exceeded 30% of control levels. To ascertain whether such inef-
ficient HR rescue was at least in part due to incomplete 53BP1
depletion, we performed HR assays in U2OS-TLR cells engi-
neered to be 53BP1 gene knock-outs (KOs) by means of CRISPR-
Cas9 genome editing (Fig. 1c−e). While BRCA1 depletion
markedly reduced HR in U2OS-TLR cells containing wild-type
(WT) 53BP1, its depletion in 53BP1 KO backgrounds resulted in
a considerably less pronounced HR defect (Fig. 1c). By contrast,
depletion of PALB2 almost completely abrogated HR in both
53BP1-proficient and 53BP1 KO cells (Fig. 1d). Taken together
with our other data, these findings indicated that 53BP1 loss
suppresses the HR defect caused by BRCA1 deficiency but not
that caused by PALB2 deficiency.
HR proficiency correlates with the ability of a cell to load the
RAD51 recombinase on DNA, which can be detected in
immunofluorescence studies as nuclear RAD51 foci13. Consistent
with our data from the HR reporter assays were our findings from
microscopy experiments in which we quantified RAD51 foci in
cyclin A-positive (to mark S- and G2-phase cells, where HR is
preferentially active) RPE1 cells depleted for various proteins and
subjected to ionising radiation (IR) to induce DNA damage.
Thus, while depletion of either BRCA1 or PALB2 resulted in a
clear defect in RAD51 IR-induced focus (IRIF) formation, only in
the case of BRCA1-depleted cells was this defect rescued by
downregulation of 53BP1 (Fig. 1f; as shown in Supplementary
Fig. 1, when we carried out studies with RPE1 cells knocked out
for BRCA1 and/or 53BP1, this also revealed that the RAD51 IRIF
formation defect caused by BRCA1 loss was rescued by 53BP1
inactivation).
Although BRCA1 is pivotal to normal regulation of the kinetics
of DSB resection in actively replicating cells exposed to agents
such as DNA restriction enzymes, DNA topoisomerase inhibitors
or PARP1 inhibitors, the protein itself is not required for the
actual process of resection but is important to counteract
inhibition of resection exerted by 53BP1 and its downstream
effectors (reviewed in ref. 5). Accordingly, DNA end-resection in
BRCA1-deficient cells occurs at a slower rate than in BRCA1-
proficient control cells4,14–16. Previous studies in which physical
lengths of ssDNA were measured via the Single Molecule Analysis
of Resection Tracks (SMART) approach4,17 demonstrated that
although ssDNA tracks were ~1.5 times shorter in BRCA1-
deficient cells than in control cells, they still encompassed tens of
microns of DNA. In agreement with these observations, we
consistently found by flow cytometry- and confocal microscopy-
based methods, either very minor or no significant effect of
BRCA1 loss on ssDNA or RPA focus formation in S/G2-phase
cells treated with IR or the topoisomerase 1 inhibitor,
camptothecin (Supplementary Fig. 1f). Nevertheless, as men-
tioned above, RAD51 IRIF formation was severely affected in
BRCA1-deficient cells, even at late time points (up to 8 h after
irradiation). Taken together with previous findings18,19, our data
thus indicated that BRCA1 is critical for RAD51 filament
formation and ensuing HR. In light of this, we concluded that
the pronounced effects of BRCA1 loss on RAD51 filament
formation and HR might largely reflect BRCA1’s crucial role(s)
associated with recruitment of the PALB2-BRCA2-RAD51
complex to RPA-coated ssDNA6,7,20.
PALB2 IRIF restoration by 53BP1 loss in BRCA1-negative
cells. Given the above results and our observation that 53BP1
depletion rescued both the RAD51 loading and HR defects of
BRCA1-deficient but not PALB2-deficient cells, we tested whe-
ther 53BP1 depletion alleviated impaired PALB2 DNA-damage
recruitment in BRCA1-deficient cells. Using RPE1 cells in which
the endogenous PALB2 gene was tagged with the green fluor-
escent protein (GFP) variant Venus (Supplementary Fig. 2a−g),
we observed that 53BP1 depletion indeed rescued the defect of
BRCA1-depleted cells in mediating PALB2 recruitment to regions
containing RPA-coated, resected DSBs (Fig. 2a, b and Supple-
mentary Fig. 2h). This was also true for untagged PALB2, assayed
by using an antibody against endogenous PALB221 to probe
RPE1 cells depleted for BRCA1 or both BRCA1 and 53BP1
(Supplementary Fig. 3a, b). Furthermore, similar results were
obtained when we examined recruitment of GFP-PALB2 to
DNA-damage tracks generated by laser micro-irradiation of
U2OS cells (Supplementary Fig. 3c, d).
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While carrying out our studies, we noticed that, upon 53BP1
depletion, PALB2 tends to form not only more numerous but also
more discernible foci (Fig. 2a, b and Supplementary Fig. 3a), as
well as brighter lines at laser tracks (Supplementary Fig. 3c, d),
which could potentially be explained by accumulation of more
PALB2 molecules at DSBs. To assess this possibility, we used
higher resolution imaging employing three-dimensional struc-
tured illumination microscopy (3D-SIM)22, which allowed us to
estimate the number of PALB2 IRIF juxtaposed to individual
RPA fibres in the nucleus. Thus, we found that 53BP1 depletion
led to an increase in the average number of PALB2 foci adjacent
to each RPA focus (Fig. 2c; Supplementary Movies). To our
knowledge, this is the first direct demonstration that 53BP1 loss
both restores PALB2 IRIF formation in BRCA1-deficient cells
and enhances PALB2 IRIF intensity in BRCA1-proficient cells.
Together, these results suggested that 53BP1 might act to directly
or indirectly interfere with PALB2 recruitment to sites containing
resected DSBs.
ChAM supports PALB2 IRIF formation in BRCA1/53BP1-
deficient cells. In light of our hypothesis that 53BP1 might
interfere with PALB2 accumulation at DSB sites, and considering
that both 53BP1 and PALB2 bind chromatin, we decided to test
whether it is the ability of PALB2 to interact with chromatin that
supports its accumulation at DSB sites in the absence of BRCA1
and 53BP1. The chromatin-binding modes of 53BP1 are well
established: its tandem Tudor domain interacts with non-damage
specific histone H4 methylated on lysine 2023, while its ubiquitin-
directed recruitment motif (UDR) is critical for 53BP1 accumu-
lation at DSB sites following RNF168-dependent ubiquitylation of
histone H2A on lysine 15 (H2AK15ub)24. In addition to its
interaction with H2AK15ub, the 53BP1 UDR also contacts the
nucleosome surface, including interactions with the acidic patch
formed by negatively charged residues in histone H2A-H2B
within the nucleosome25. By contrast, chromatin-binding by
PALB2 is modulated by a short region termed the Chromatin
Associated Motif (ChAM)26, and PALB2 can also be recruited to
chromatin by its interacting partner MRG15, a protein found in
several chromatin-modifying and chromatin-remodelling
complexes27,28. Thus, we assessed how efficiently GFP-PALB2
derivatives lacking either the ChAM or the MRG15-interacting
domain, or both (Fig. 3a and Supplementary Fig. 4), formed IRIF
in the presence or absence of 53BP1 and BRCA1. As
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Fig. 1 53BP1 loss corrects HR in BRCA1- but not in PALB2- or BRCA2-deficient cells. a HR reporter assay in U2OS-TLR WT cells siRNA-depleted for
indicated proteins or treated with a control siRNA (siCTRL). The bars represent mean ± st.dev.; unpaired t test analyses were conducted to determine if
differences between samples were statistically significant; n≥ 3 experiments. Individual data points are plotted over bars. b Immunoblot of extracts of
U2OS-TLR cells depleted for indicated proteins and used in HR assays shown in (a). Asterisks mark nonspecific bands. c, d Comparison of HR efficiencies
measured by TLR assays performed in U2OS-TLR WT and 53BP1 KO cells siRNA-depleted for either BRCA1 (c) or PALB2 (d). Data representation and
statistical analyses are as in (a); n≥ 4 experiments. e Immunoblot of extracts of U2OS-TLR WT and 53BP1 KO cells siRNA-depleted for BRCA1 and PALB2
and used in HR assays in (c, d). f Quantification of RAD51 IRIF in RPE1 cells siRNA-depleted for indicated proteins. Cells were treated with 6 Gy of IR, fixed
at 4−8 h after irradiation, stained with antibodies specific to cyclin A and RAD51 proteins, imaged and quantified using OPERA Phoenix HT microscope; n
= 4 repeats. Source data are provided as a Source Data file. **P < 0.01, ***P < 0.001, ****P < 0.0001; ns, not significant (P≥ 0.05).
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expected26,29, in BRCA1/53BP1-proficient (WT) RPE1 cells,
deletion of either the ChAM or MRG15-binding domain had a
modest effect on PALB2 IRIF formation, whereas lack of both
regions had a more pronounced effect (Fig. 3b, c and Supple-
mentary Fig. 4a). In stark contrast, in the absence of both BRCA1
and 53BP1, PALB2 recruitment to IRIF was dramatically
impaired by deletion of its ChAM domain and was also dimin-
ished somewhat upon deletion of the MRG15-interacting region
(Fig. 3d, e and Supplementary Fig. 4b). Notably, in BRCA1/53BP1
double KO cells, a PALB2 derivative lacking both ChAM and
MRG15-binding domains had an IRIF formation defect no worse
than that of the single ChAM deletion mutant (Fig. 3d, e) high-
lighting the key importance of the ChAM domain in this parti-
cular genetic background. Based on these findings, we concluded
that while the main recruitment mode for PALB2 to DSB sites is
normally via its physical interaction with BRCA1, in the absence
of BRCA1, PALB2 accumulation at DSBs strongly depends on its
intrinsic chromatin-binding properties mediated by the ChAM
region.
To assess the biological relevance of these observations and
conclusions, we examined impacts on cellular sensitivity to the
PARP1 inhibitor olaparib, which induces DNA damage that is
normally repaired by HR mechanisms in S-phase26,30. In
agreement with our other observations, complementation of
PALB2-depleted RPE1 cells with PALB2ΔChAM did not confer
significant olaparib sensitivity when BRCA1 was present (Fig. 3f).
By contrast, when parallel studies were performed with cells
lacking BRCA1 and 53BP1, wild-type PALB2 imparted olaparib
resistance while PALB2ΔChAM did not (Fig. 3g). Collectively,
these results indicated that when PALB2 cannot be recruited to
DNA-damage sites by BRCA1, 53BP1 functions to antagonise
PALB2 binding to DNA lesion-proximal chromatin and thereby
impairs HR. They also suggested that, when BRCA1-deficient
cells also lack 53BP1, PALB2 is recruited to DSB regions where it
forms IRIF in a manner dependent on its ChAM region and
promotes HR.
PALB2 ChAM domain contacts the nucleosome acidic patch.
To complement our cell-based studies and to further investigate
the chromatin-binding properties of the PALB2 ChAM region,
we characterised the ability of bacterially expressed and purified
6xHis-MBP-tagged PALB2 ChAM protein to interact with
defined recombinant nucleosome core particles (NCPs) in vitro.
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Fig. 2 53BP1 depletion rescues PALB2 focus formation in BRCA1-deficient cells. a Quantification of Venus-PALB2 IRIF in RPA focus-positive RPE1 cells.
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OPERA Phoenix HT microscope. b Representative images, acquired on OPERA Phoenix HT microscope, of RPE1 cells with endogenously Venus-tagged
PALB2 gene. The cells were stained with anti-GFP (to enhance the signal of the Venus tag) and anti-RPA2 antibodies. Scale bar, 50 µm. c Venus-PALB2
association with RPA filaments in cells depleted for 53BP1. RPE1 cells expressing endogenously tagged Venus-PALB2 were depleted for BRCA1 and/or
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RPA focus. Source data are provided as a Source Data file.
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Thus, we found that the ~50 amino acid residue ChAM domain
was sufficient to retrieve NCPs in biochemical pull-down assays
(Fig. 4a). Furthermore, removing the N-terminal tails of either
histone H3 or H4 did not impair ChAM binding, suggesting that
the interaction may be mediated by the core nucleosome surface.
Having considered that the ChAM domain is highly positively
charged (with a predicted pI of 9.6; ExPasy) and that the
nucleosome acidic patch is a common site of contact for
chromatin-binding proteins, including 53BP131,32, we tested
whether the interaction between ChAM and NCPs was affected
when the negative charge of the H2A-H2B acidic patch (Fig. 4b)
was reduced by mutating key residues (H2A Glu61, 90, 91 and
H2B Glu105 to Ala). Notably, we found that mutating the acidic
patch ablated ChAM domain binding to NCPs (Fig. 4a), implying
that the ChAM−nucleosome interaction is at least in part
mediated by the acidic patch. As PALB2 IRIF formation appears
to be dependent on RNF16833,34, which is recruited to DSBs and
ubiquitylates H2A at Lys15, we tested if histone H2A Lys15
ubiquitylation affected PALB2 ChAM binding in vitro and found
that both unmodified and H2A Lys15-ubiquitylated NCPs bound
ChAM comparably (Supplementary Fig. 5a). Collectively, our
data indicated that the PALB2 ChAM binds chromatin inde-
pendently of H2A Lys15 ubiquitylation status, but binding
requires an intact H2A-H2B acidic patch.
Reasoning that the nucleosome acidic patch might be
recognised at least in part via electrostatic interactions with
positively charged amino acid residues in the PALB2 ChAM
region, we mutated four conserved basic residues in the ChAM
domain (Fig. 4c), and found that these mutations resulted in
considerable attenuation of the ChAM-nucleosome interaction
(Supplementary Fig. 5b). In agreement with our in vitro binding
experiments, cells complemented with PALB2 containing these
four mutations (PALB24M; Fig. 4c) exhibited properties similar to
those of PALB2ΔChAM (Fig. 4d, e and Supplementary Fig. 5c).
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(AUC); n≥ 3. The bars represent mean ± s.e.m.; one-way ANOVA; *P < 0.05, **P < 0.01, ****P < 0.0001; ns, not significant (P≥ 0.05); n= 3 independent
experiments. Source data are provided as a Source Data file.
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Thus, while PALB2ΔALB2 and PALB24M both largely alleviated
the olaparib hypersensitivity of BRCA1/53BP1-proficient cells
depleted of endogenous PALB2 protein (Fig. 4d), neither achieved
this in the BRCA1/53BP1 double knock-out background (Fig. 4e).
To gain further insight into the nature of the ChAM−NCP
interaction, we tested whether it was affected by mutating basic
residues Arg414 and Arg421 to either alanine (to remove the
charge) or lysine (to preserve the positive charge). We found that
both R414A and R414K mutants had lost their ability to bind
NCPs (Fig. 4f), suggesting that Arg414 may play a critical
structural role in the ChAM−NCP interaction. By contrast, while
the R421A mutation reduced ChAM−NCP binding, the R421K
mutant retained NCP binding potential (Fig. 4f), suggesting that
this residue functions primarily via forming electrostatic interac-
tions with the negatively charged H2A-H2B acidic patch.
In further biochemical pull-down studies, we explored
potential contributions to NCP binding of several other residues
within the highly conserved core of the PALB2 ChAM region.
Thus, we found that alteration of several residues centred around
Arg414 (mutations V410A, T413A and S417A) compromised the
interaction with recombinant NCPs (Fig. 4g). Interestingly,
cancer-associated mutations in this region have been previously
reported to exhibit reduced chromatin association in chromatin
fractionation studies29. In line with this, we observed that
reported missense mutations35 T413S, R414Q and S417Y, but not
V425M, displayed reduced interaction with NCPs in vitro
(Supplementary Fig. 5d).
Discussion
The key hallmark of BRCA1-deficient cells is their inability to
repair DNA damage via HR. Such an impairment can be
explained by the pivotal roles BRCA1 plays in two major steps of
HR: firstly, it stimulates end-resection of DSBs, thus fostering the
generation of ssDNA required for HR-mediated homology
search; secondly, BRCA1 promotes recruitment of PALB2 and
BRCA2 to DNA-damage sites, which in turn help load RAD51
recombinase onto resected ssDNA (reviewed in ref. 36). When it
was first demonstrated that loss of 53BP1 corrects HR defects of
BRCA1-deficient cells and suppresses lethality of Brca1−/− mice,
it was postulated that restoration of DNA end-resection was the
key event mediating these impacts8,9. While this served as a useful
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starting model, further extensive research, which includes a very
recent study describing roles for 53BP1 both pre- and post-DNA
end-resection37, has unravelled a much more complex relation-
ship between BRCA1, 53BP1 and the processes of HR (reviewed
in refs. 5,36). In agreement with several studies showing that DNA
end-resection takes place in BRCA1-deficient cells, albeit with
delayed kinetics,4,14–16, we could detect similar amounts of
chromatinised RPA in BRCA1-proficient and -deficient cells that
had been treated with DSB-inducing agents and allowed to pro-
cess the lesions for several hours. However, even at the late time
points, BRCA1-deficient cells failed to form RAD51 IRIF unless
they were co-depleted for 53BP1. This strongly suggested that, in
addition to slowing down initial DSB resection, 53BP1 could also
interfere with RAD51 loading in BRCA1-deficient cells. Thus, we
set out to gain a better mechanistic understanding of how 53BP1
loss restores RAD51 recruitment in BRCA1-deficient cells.
Our results support a model in which RAD51 nucleoprotein
filament formation and HR are restored in BRCA1-deficient cells
following 53BP1 loss via a mechanism underpinned by recovery
of PALB2 recruitment to DSB-proximal chromatin mediated by a
direct interaction between the PALB2 ChAM and the nucleosome
acidic patch region. In this model, in the absence of BRCA1,
53BP1 is not efficiently displaced from chromatin adjacent to
DSBs17,38 and therefore remains bound to nucleosomes via both
its Tudor and UDR domains, with the latter helping to occlude
the H2A-H2B acidic patch, which is recognised by various
chromatin-interacting proteins32. We propose that, upon loss of
53BP1, the surfaces on nucleosomes where it binds, including the
acidic patch, become more available for interaction with other
less abundant or not as avidly binding factors, including PALB2.
Many chromatin-binding proteins described to date interact
with nucleosomes via the acidic patch31,39. A common structural
arrangement is the insertion of an arginine anchor into the acidic
patch, with stabilising interactions formed by other positively
charged residues. Interestingly, in the conserved core of the
ChAM domain, we find two arginine residues, Arg414 and
Arg421, mutations of which reduce the ChAM interaction with
nucleosomes. Intriguingly, while the ChAM−NCP interaction
takes place in the context of the conservative R421K substitution,
NCP binding was ablated by changing Arg414 to alanine, lysine
or glutamine (the latter is a mutation found in a cancer patient35).
This suggests that the structure of Arg414 itself, rather than
simply its electrostatic charge, plays a key role in binding to the
nucleosome. Further work is required to determine the exact
nature of ChAM binding to nucleosomes, whether the interaction
is solely focused on the acidic patch, and if Arg414 is indeed
operating as an arginine anchor.
While the ChAM domain is sufficient for interaction with
recombinant NCPs in vitro, it is likely that PALB2 chromatin
recruitment in cells is multivalent in nature. Most chromatin-
binding proteins/complexes described to date recognise multiple
interfaces to ensure both affinity and specificity of their recruit-
ment to the correct subcellular location32. PALB2 binds to
nucleosomes in our in vitro assays with low affinity, requiring
large amounts of immobilised PALB2. In vivo, other PALB2
interaction interfaces, including direct interaction with DNA40
and other DDR factors33,34,41,42, likely ensure appropriate PALB2
recruitment to sites of DSBs. Our data support a model in which
PALB2’s interaction with BRCA1 plays a dominant role in
PALB2 recruitment to DNA-damage sites under normal cir-
cumstances, while when BRCA1 and 53BP1 are absent, normally
stabilising interactions, such as between the ChAM domain and
the nucleosome acidic patch, are likely to become more essential
for DSB recruitment.
Clearly, if PALB2 recruitment in BRCA1/53BP1-deficient cells
were mediated only by its interaction with the H2A-H2B acidic
patch, it would be expected to bind chromatin throughout the
whole nucleus; however, following DSB induction, PALB2 forms
foci adjacent to RPA-coated ssDNA. Such targeted accumulation
is probably mediated by the interaction with other DSB recruited
factors or recognition of induced histone post-translational
modifications. In line with this hypothesis, it has been reported
that there is a direct interaction between RNF168 and PALB2 33,
and we and others have observed that loss of RNF168 attenuates
IRIF formation by PALB2 and re-sensitises BRCA1/53BP1-defi-
cient cells to PARP inhibitors34 (Supplementary Fig. 6a−d).
One consideration important to our model is that, when 53BP1
is recruited to DSB-proximal chromatin, it will localise there
together with components of the recently described Shieldin
complex, with 53BP1-RIF1 bound to chromatin and REV7-
SHLD1/2/3 contacting the ssDNA of partially resected DSBs43.
As 53BP1 works together with the rest of its downstream co-
factors to block over-resection of DNA DSBs, loss of any of these
proteins partially restores RAD51 filament formation, functional
HR and PARP-inhibitor resistance in BRCA1-deficient cells.
Notably, whereas recruitment of RIF1, REV7 and SHLD1/2/3
depends on intact 53BP1, losing the downstream proteins does
not prevent 53BP1 from forming IRIF44–47. Thus, in the absence
of its co-factors, 53BP1 is still bound to DSB-proximal chromatin
and therefore might interfere with efficient PALB2 recruitment,
especially in BRCA1-deficient settings. Importantly, according to
a recent study that employed super-resolution microscopy to
characterise chromatin conformations orchestrated by 53BP1 and
its co-factors, 53BP1 accumulates near DSB sites and, together
with RIF1, forms topologically associating domains (TADs) of
compacted chromatin47. Whereas the integrity of these TADs is
fully dependent on 53BP1 and is partially compromised by RIF1
depletion, loss of Shieldin components does not affect 53BP1/
RIF1-mediated chromatin compaction47. In line with these
observations and our model that loss of 53BP1 in BRCA1-
deficient cells creates permissive conditions for PALB2 accumu-
lation on chromatin, we see that only co-depletion of 53BP1 fully
rescues Venus-PALB2 and RAD51 foci in BRCA1-depleted
RPE1 cells, while RIF1 depletion has a weaker effect and the
loss of REV7 or Shieldin components does not allow detectable
recruitment of PALB2 to DSB-proximal chromatin (Supple-
mentary Fig. 7). Our findings are in agreement with studies
demonstrating that losing 53BP1 has the strongest overall effect
in rescuing BRCA1-deficient phenotypes45,48,49. Accordingly, we
propose that upon depletion of RIF1, REV7 or SHLD1/2/3 in
BRCA1-deficient cells, PALB2 accumulation into IRIF on DSB-
proximal chromatin is attenuated by 53BP1 but under such cir-
cumstances, partial rescue of HR is brought about by Shieldin loss
allowing some PALB2/RAD51 loading directly onto ssDNA
generated at DSB sites. Consistent with this notion are findings
suggesting that Shieldin might interfere with RNF168-mediated
PALB2 recruitment to resected DNA37. Further studies are nee-
ded to define the precise mechanisms underpinning these effects,
and to establish whether and how they may relate to PARP-
inhibitor resistance in clinical settings.
Methods
Cell culture. U2OS and HEK293 cell lines were originally obtained from the ATCC
cell repository and routinely tested to be mycoplasma-free. RPE1 FRT/TR cells
were described in ref. 50. All cells were maintained at 37 °C in a humidified
atmosphere containing 5% CO2. U2OS, U2OS-derived and HEK293T cells were
cultured in standard Dulbecco modified Eagle’s minimal essential medium
(DMEM) (Sigma-Aldrich). RPE1 and RPE1-derived cells were cultured in Ham’s
Nutrient Mixture F12 medium (Sigma-Aldrich) supplemented with 17.5 ml of 7.5%
NaHCO3 solution per 500 ml (Sigma-Aldrich). All media were supplemented with
10% fetal bovine serum (FBS; BioSera), 2 mM L-glutamine, 100 Uml−1 penicillin,
and 100 μg ml−1 streptomycin (Sigma-Aldrich). Tetracycline-negative FBS from
PAA Laboratories was used for U2OS cells stably expressing tetracycline repressor
(U2OS-Trex) and derived inducible stable cell lines. Additional supplements used
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to maintain stable cell lines were as follows: 2 μg ml−1 puromycin (Sigma-Aldrich)
for U2OS TLR cells; 2 μg ml−1 blasticidin (Invitrogen) for U2OS-Trex cells; 0.2 mg
ml−1 zeocin (Life technologies) and 2 μg ml−1 blasticidin (Invitrogen) to select
U2OS-Trex cells stably expressing inducible EGFP-PALB2; 0.6 mg ml−1 G418
(Invitrogen) to select RPE1 FRT/TR cells with stable inducible expression of EGFP-
PALB2 derivatives. To induce EGFP-PALB2 expression, doxycycline (Sigma-
Aldrich) was added at a final concentration of 0.1− 0.01 μg ml−1.
Plasmids and cloning. EYFP-PALB2 was subcloned from pEYFP-PALB2WT
plasmid26 (a gift from F. Esashi) into pcDNA4-TO (Thermo Fisher Scientific) and
pcDNA5-FRT/TR-neo plasmids (pcDNA5/FRT/TO-neo (1795) was a gift from
Jonathon Pines (Addgene plasmid # 41000; http://n2t.net/addgene:41000; RRID:
Addgene_41000)). PALB2 derivatives lacking ChAM domain (residues 395−445),
MRG15-binding domain (residues 629−764) or both were generated by fusion
PCR51. Details of primers used for cloning and mutagenesis could be provided
upon request. PALB2 ChAM sequence (residues 395−445) was optimised for
codon usage (R431 AGG-CGT) and inserted into pET 6xHis MBP TEV LIC
cloning vector (addgene gift of Scott Gradia) via ligation independent cloning.
Point mutations were introduced using QuickChange Lightning Site-Directed
Mutagenesis kit (Agilent).
siRNA and plasmid transfections. Unless the sequences for siRNA oligonu-
cleotides had come from previous publications, siRNA oligonucleotides were
designed using either the MWG (Erofins) or Dharmacon design centre and pur-
chased from MWG Biotech (Erofins). siRNA transfections were performed using
Lipofectamine RNAiMAX (Life Technologies) at a final siRNA concentration of
∼50 nM according to the manufacturer’s instructions. siRNA-transfected cells were
re-plated for assays 48 h after transfection and treated and processed 24 h after re-
plating (72 h after transfection). DNA transfections were performed using TransIT-
LT1 (Mirus Bio) following the manufacturer’s guidelines. As a negative control, we
used siRNA oligonucleotides targeting Luciferase (CTRL siRNA). For a complete
list of siRNA sequences used in this study, see Supplementary Table 1.
Stable cell line generation. U2OS-Trex cells stably expressing inducible EYFP-
PALB2 derivatives were generated by transfection of pcDNA4/TO/EYFP-PALB2
plasmid into the cells, re-plating cells at low density 48 h later and selecting stable
integrants at 0.2mgml−1 zeocin for 10−14 days. RPE1 FRT/TR p53KO cells were co-
electroporated, using NEON system (Thermo Fisher Scientific), with flippase-
expressing pOG44 plasmid (Thermo Fisher Scientific) and pcDNA5-FRT/TO-neo
containing EYFP-tagged PALB2 constructs; stable clones were selected at 0.6mgml−1
G418 for 7−10 days. Individual colonies were picked, expanded and tested for
protein expression upon induction with doxycycline.
CRISPR-Cas9-mediated gene knock-outs and endogenous tagging. Gene
knock-outs (KO) were generated following the protocol described in ref. 52. Briefly,
U2OS/TLR and RPE1 p53 null cells were transfected or electroporated with the All-
in-One plasmids expressing either EGFP or mCherry fluorescent marker,
Cas9D10A nickase and two guide RNAs specific for the gene(s) of interest. Forty-
eight hours later, cell cultures were single-cell FACS-sorted for single or dual
fluorescence and allowed to form colonies on 96-well plates. To verify the KOs,
individual clones were analysed by a combination of high-throughput immuno-
fluorescence microscopy, immunoblot and PCR approaches. In case of BRCA1 KO,
cell lines, which lacked full-length BRCA1 protein (as detected by immunoblotting)
and showed altered pattern of DNA fragments generated in PCR across the tar-
geted genomic locus, were also profiled for their sensitivity to PARP1 inhibitor
olaparib.
To tag PALB2 at its endogenous gene locus, RPE1 cells were electroporated with
two plasmids: the mCherry-expressing All-in-One Cas9 nickase vector with gRNAs
targeting the first exon of PALB2 gene and the vector with the Venus tag-encoding
sequence sandwiched between the long homology arms which comprised the
sequences flanking the gRNA-targeted site (see Supplementary Fig. 2a for graphic
details). In the targeting template, two guanines of the PAM motif for the gRNA-
Sense were mutated using side-directed mutagenesis kit (Invitrogen) to avoid
nicking of the homology donor. Insertion of the Venus open reading frame at the
start of PALB2 coding sequence destroyed the target site for the antisense gRNA.
Forty-eight hours after electroporation, the cells that expressed both mCherry and
Venus markers (1.3%) were plated on four 96-well plates at a single cell per well
density. After 2 weeks, a total of 47 surviving colonies were picked and expanded
for PCR and further analyses. According to the PCR analysis, 19 out of 47 clones
appeared to have both alleles of PALB2 gene tagged with Venus. PCR fragments
were further analysed by restriction digestion and Sanger sequencing. The
functionality of endogenously tagged Venus-PALB2 protein was characterised by
immunoprecipitation (interaction with BRCA1, BRCA2 and MRG15 proteins) and
immunofluorescence (IR-induced focus formation in S/G2 cells).
Sequences of primers used to generate sgRNAs can be found in Supplementary
Table 2.
Antibodies. Information regarding primary antibodies used in this work can be
found in Supplementary Table 3.
DNA-damage induction and drug treatments. For ionising radiation treatments,
a Faxitron-CellRad (Faxitron Bioptics, LLC) fitted with an aluminium filter for soft
X-rays was used. Localised DNA damage was generated by exposure of cells to a
UV-A laser beam in laser micro-irradiation experiments performed essentially as
described in ref. 53. In brief, cells were plated on glass-bottomed dishes (Willco-
Wells) and pre-treated with 10 µM 5-bromo-2′-deoxyuridine (BrdU, Sigma-
Aldrich) for 24−36 h. Laser micro-irradiation was performed using a FluoView
1000 confocal microscope (Olympus) equipped with a 37 °C heating stage (Ibidi)
and a 405-nm laser diode (6 mW) focused through a 360 UPlanSApo/1.35
numerical aperture lens. The time of cell exposure to the laser beam was around
250 ms (fast scanning mode). To induce S-phase-specific DSBs, cells were treated
with 1 μM camptothecin (Sigma-Aldrich) for 1 h.
Clonogenic survival assays. Cells were seeded at low density in six-well plates at
two different dilutions, treated with various concentrations of PARPi (olaparib;
Stratech Scientific) and allowed to form colonies for 7−10 days. Colonies were
stained with 0.5% crystal violet/20% ethanol and counted. Results were normalised
to plating efficiencies.
TLR assays. To evaluate HR efficiency upon siRNA-mediated depletion of various
proteins, the TLR assays based on the system described in ref. 10 were performed.
The workflow was as described in ref. 11. Briefly, U2OS-TLR cells were transfected
with control siRNA (targeting firefly luciferase gene) or various other siRNAs and 6
−8 h later were co-transfected with expression plasmids containing: infrared
fluorescent protein (IFP) and I-SceI endonuclease; and blue fluorescent protein
(BFP) together with the donor sequence. Cells were collected ∼72 h after siRNA
transfection. Four-colour fluorescent flow cytometry using a BD LSRFortessa cell
analyser (BD Biosciences) allowed direct measurements of the percentages of GFP
+ (HR). A minimum of 10,000 doubly transfected (IFP+ and BFP+) cells were
scored for each condition in a minimum of three experiments. Data analysis was
performed using FlowJo X (Tree Star).
Immunoblotting. Total cell lysates were prepared using SDS lysis buffer (4% SDS,
20% glycerol, and 120 mM Tris-HCl, pH 6.8), heating for 5 min at 95 °C and
fragmenting gDNA by passing lysates several times through a 19-gauge needle.
Absorbance at 280 nm was measured on NanoDrop (Thermo Fisher Scientific) to
determine protein concentration. Samples were resolved on 4−12% Bis-Tris gels
NuPAGE gels (Novex, Life Technologies) and transferred onto nitrocellulose
membranes (GE Life Sciences) or polyvinylidene difluoride (PVDF). Membranes
were blocked with either 1−5% bovine serum albumin (BSA) or 3−5% milk in
TBS/0.1% Tween-20 (TBST) and incubated with the relevant primary antibody
(Supplementary Table 2) followed by several TBST washes and incubation with
corresponding horse radish peroxidase-conjugated secondary antibody (Fisher
Scientific). Enhanced chemiluminescence (ECL) reagent (GE Healthcare) was used
for detection.
Immunofluorescence. For confocal and 3D-SIM microscopy, cells were grown on
poly-lysine-coated coverslips; for automated high-throughput IRIF detection and
counting using OPERA system, cells were plated in 96-well plates (Cell Carrier,
Perkin Elmer). For detection of RPA2 and PALB2, cells were washed with
phosphate-buffered saline (PBS), pre-extracted for 2 min on ice in CSK buffer (25
mM HEPES pH 7.4, 50 mM NaCl, 1 mM EDTA, 3 mM MgCl2, 300 mM sucrose)
containing 0.25% Triton X-100, and fixed with 2% formaldehyde for 15 min at
room temperature. For staining with all other antibodies, pre-extraction step was
omitted. Fixed cells were washed three times with PBS containing 0.1% Tween-20
(PBST), permeabilised with 0.2% Triton X-100 in PBS for 5 min and blocked with
0.2% fish skin gelatin in PBS for 30 min to overnight. One-hour incubation with
primary antibodies was followed by three washes with PBST and 30-min incuba-
tion with secondary, Alexa-Fluor-conjugated, antibodies (Molecular Probes) at
1:1000 dilution and 1 μg ml−1 containing 4,6 diamidino-2-phenylindole (DAPI,
Sigma-Aldrich). After three final washes with PBST, the coverslips were rinsed in
deionized water and mounted on glass slides using DAPI-free VectaShield
mounting medium (Vector Laboratories).
Automated high-throughput microscopy for IRIF quantification. For high-
throughput imaging and analyses of focus formation by RPA2, RAD51 and PALB2
proteins, cells were plated on 96-well Cell Carrier (Perkin Elmer) plates at a density
of 7500−10,000 cells/well. The following day, cells were either mock-treated or
irradiated (6 Gy) and processed for imaging as described under Immuno-
fluorescence method. Imaging was performed on the spinning disk Opera Phenix
microscope (Perkin Elmer) using either ×20 or ×40 water immersion objectives.
Images were acquired in single optimised focal plane for each of the three channels
(405, 488 and 568 nm) in the confocal mode. Image analysis and evaluation was
done using Harmony High-Content Imaging and Analysis software. In each
experiment, 7−10 fields (>500 cells) per well were acquired and analysed.
Confocal microscopy. The confocal images were acquired on an Olympus FV1000
upright confocal microscope using ×40 or ×60 UPlanSApo/1.35 oil objective. For
ARTICLE NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-020-14563-y
8 NATURE COMMUNICATIONS |          (2020) 11:819 | https://doi.org/10.1038/s41467-020-14563-y | www.nature.com/naturecommunications
the experiment presented in Fig. 3b−e, image analysis and quantification were
performed using a custom script (https://github.com/gurdon-institute/
Intensity_Distribution) for Fiji54. This high-throughput macro segments nuclei in
the DAPI channel by Otsu thresholding and segments GFP-PALB2 foci in the
green (488 nm) and RPA2 foci in red (594 nm) channels by detecting local intensity
maxima as seed points to trace uniform regions with a tolerance of half the global
channel mean. For each red focus, the distance to the nearest green focus is
measured and a call for closeness is made using a cutoff distance of 0.5 µm.
Integrated density (area ×mean intensity) is measured for each green focus.
3D/SIM super-resolution microscopy. Super-resolution 3D SIM imaging of
Venus-PALB2 and RPA was performed using a Deltavision OMX 3D SIM System
V3 (GE) equipped with 3 EMCCD Cascade cameras from Photometrics, 405, 488,
593 nm diode laser illumination, an Olympus PlanSApo ×100 1.42 NA oil objec-
tive, and standard excitation and emission filter sets. Imaging of each channel was
performed sequentially using three angles and five phase shifts of the illumination
pattern as described in ref. 22. The refractive index of the immersion oil (Cargille)
was adjusted to 1.514 to minimise spherical aberrations. Sections were acquired at
0.125 μm z steps. Raw OMX data were reconstructed and channel registered in the
SoftWoRx software (GE). Reconstructions were carried out using channel-specific
optical transfer functions (OTFs) and channel-specific K0 angles. OTFs were
generated within the SoftWoRx software by imaging 100 nm beads (Life Tech-
nologies) using appropriate immersion oils to match the data. Channel registration
was carried out using the Image Registration parameters generated within the
SoftWoRx software and checked for accuracy by imaging Tetraspeck beads (Life
Technologies). Channel registration was accurate to within one pixel. Further data
analysis was performed using a Fiji plugin Surrounding Blobs (https://github.com/
gurdon-institute/Surrounding_Blobs) that we developed for high-throughput seg-
mentation and measurement of 3D foci in OMX images. Local intensity maxima
are mapped in 3D to seed assignment of nearby thresholded voxels, and the
number of green (488 nm) foci within 200 nm of each red (593 nm) focus is
measured.
6xHis-MBP-ChAM purification. 6xHis-MBP and 6xHis-MBP-ChAM protein
variants were induced in BL-21 DE3 RIL cells using 200 μM IPTG overnight at 16 °
C. Cell pellets were resuspended in lysis buffer (25 mM phosphate buffer pH 7.4,
300 mM NaCl, 0.1% Triton (v/v), 10% glycerol (v/v), 5 mM β-mercapthoethanol,
1× Protease Inhibitor mix [284 ng ml−1 leupeptin, 1.37 μg ml−1 pepstatin A, 170
μg ml−1 phenylmethylsulfonyl fluoride and 330 μg ml−1 benzamindine], 1 mM
AEBSF and 5 μg ml−1 DNaseI) Cells were lysed by sonication and lysozyme
treatment. Clarified lysate was applied to a HiTrap chelating column (GE
Healthcare) pre-loaded with Ni2+ ions, or Ni-NTA resin (Qiagen). After extensive
washing 6xHis-MBP-ChAM was eluted using 300 mM imidazole and concentrated
a 30 K MWCO centrifugation device (Amicon). 6xHis-MBP-ChAM was further
purified on by size exclusion chromatography using a superdex 200 Increase 10/300
in SEC buffer (20 mM Tris pH 7.5, 150 mM NaCl, 1 mM dithiothreitol (DTT), 5%
glycerol) and the main mono-disperse protein containing peak was collected,
concentrated, flash frozen in liquid nitrogen and stored at −80 °C.
Protein concentrations were determined via absorbance at 280 nm using a
Nanodrop 8000 (Thermo Scientific), followed by SDS-PAGE and InstantBlue
(Expedeon) staining with comparison to known amounts of control proteins.
Chemical ubiquitylation of histone H2A. Mutant human Histone H2A engi-
neered with a single cross-linkable cysteine (H2A K15C) was chemically ubi-
quitylated essentially as described25,55. Briefly, an alkylation reaction was
assembled with H2A K15C (700 μM), 6xHis-TEV-ubiquitin G76C (700 μM) and
1,3-dibromoacetone (4.2 mM, Santa Cruz) in 250 mM Tris-Cl pH 8.6, 8 M urea
and 5 mM TCEP (tris(2-carboxyethyl)phosphine) and allowed to react for 16 h
on ice. The reaction was quenched by the addition of 10 mM β-mercaptoethanol
and pH adjusted to 7.5. Chemically ubiquitylated H2A (H2A Kc15ub) was
purified using a HiTrap SP HP column (GE Healthcare) and 6xHis-TEV-
H2AKc15ub containing fractions were pooled and enriched over a HiTrap
chelating column (GE Healthcare) pre-loaded with Ni2+ ions. The 6xHis tag was
removed by TEV cleavage and subsequent Ni2+ column subtraction. The
resulting flow-through was dialysed against a 2 mM β-mercaptoethanol/
dH20 solution and lyophilised. H2A Kc15ub was refolded and wrapped into
NCPs as described below.
NCP reconstitution. Nucleosome core particles (NCPs) were reconstituted
essentially as described25. Briefly the four core human histones were expressed
in BL-21 DE3 RIL cells and purified from inclusion bodies as described56. 145
bp Widom-601 DNA fragments for wrapping nucleosomes were generated by
either cleavage of pUC57-8 × 145 bp Widom-601 DNA57 and purification56 or
by PCR-based amplification58,59. Briefly for PCR amplification, 384 100-μl
PCR reactions using Pfu polymerase and HPLC pure oligos (IDT) were pooled,
filtered and purified using a ResourceQ column and DNA was eluted using a
salt gradient.
For octamer formation, histones were mixed at equimolar ratios in unfolding
buffer (7 M Guanidine HCl, 20 mM Tris pH 7.5, 5 mM DTT) prior to dialysis to
promote refolding into 2 M NaCl, 15 mM Tris pH 7.5, 1 mM EDTA, 5 mM β-
mercaptoethanol. Octamers were selected by gel filtration chromatography
and assembled into NCPs via salt gradient dialysis60. Soluble NCPs were
partially polyethylene glycol (PEG) precipitated25,61 and resuspended in 10 mM
HEPES pH 7.5, 100 mM NaCl, 1 mM EDTA, 1 mM DTT. NCP formation and
quality was checked by native gel electrophoresis and used within 1 month of
wrapping.
NCP pull-down assays. Pull-down assays were either performed with PALB2
immobilised directly from expressed Escherichia coli extract on Ni-NTA resin
(Fig. 4f, g and Supplementary Fig. 5d) or with fully purified 6xHis-MBP-tagged
PALB2 ChAM immobilised after gel filtration chromatography, concentration,
quantification and freezing (Fig. 4a and Supplementary Fig. 5a, b). For Fig. 4f, g
and Supplementary Fig. 5d, 6xHis-MBP ChAM variants were lysed as for 6xHis-
MBP-ChAM purification and lysate bound in batch to Ni-NTA beads to saturation
(roughly 12 μg protein per μl beads). Beads were washed extensively and amount of
protein quantified and normalised by comparison on SDS-PAGE, against known
purified MBP-ChAM. Pre-immobilised beads were used immediately or the next
day, diluted so that 35−40 μg of MBP-ChAM protein per 15 μl of Ni-NTA beads
was used per pull-down.
For purified his-MBP-ChaM pull-downs, 25 μg of 6xHis-MBP-tagged PALB2
ChAM proteins were immobilised on Ni-NTA resin (Qiagen) or Amylose resin
(NEB) for 1 h. All pull-down assays were incubated with 2.2 μg of NCP complex in
pull-down buffer (20 mM Tris-Cl pH 7.5, 120 mM KCl, 2 mM β-mercaptoethanol,
10% glycerol (v/v), 0.01% NP-40 (v/v), 100 μg/ml BSA, 15 mM imidazole) for 2 h at
4 °C. Pull-downs were washed thoroughly in pull-down buffer and resuspended
directly in 2× SDS loading buffer. All pull-down assays were repeated at least twice,
with a single immunoblot displayed.
Statistics and reproducibility. Statistical analyses were performed using Graph-
Pad Prism version 8 for Mac OS X, GraphPad Software (La Jolla, CA, USA).
Reporting summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
All the data supporting the findings of this study are either available within the paper and
its Supplementary Information files or can be obtained from the authors upon request.
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